Efficacy and Safety of Tirzepatide Monotherapy Compared With Dulaglutide in Japanese Patients With Type 2 Diabetes (SURPASS J-Mono): A Double-Blind, Multicentre, Randomised, Phase 3 Trial
In pancreatic cells, activation of these G proteincoupled receptors is primarily mediated through pathways involving cyclic adenosine monophosphate (cAMP), protein kinase A ( PKA ), and cAMP response elementbinding protein ( CREB ), thereby enhancing glucose-dependent insulin secretion and supporting -cell function
Semaglutide is a glucagon-like peptide-1 (GLP-1) agonist that has been approved by the US Food and Drug Administration (FDA) for the treatment of obesity and type 2 diabetes
Brandon Richland, MD Tirzepatide is a relatively new medication that has shown promise in the management of type 2 diabetes and weight loss
However, we cannot exclude that this could also be a consequence of the improvements in glucose regulation restoring the glucosuppressive effect on glucagon that may also be influenced by diet 59